ClinicalTrials.gg
CompletedNCT03038399Updated May 20, 2021Results posted

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase 2 interventional study of Vamorolone 0.25 mg/day/day and Vamorolone 0.75 mg/day/day in Duchenne Muscular Dystrophy, sponsored by ReveraGen BioPharma, Inc.. Completed at 12 sites in 6 countries. Open to male participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2021-05-20.

Sponsored by ReveraGen BioPharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
4 Years to 7 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
62nd of 171
46 · median 25
Started
2017
with 10 others
Phase 2
57 of 232
4 open now
Registered
113th of 232
by date

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 62nd largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 57 in phase 2, and was the 113th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 7 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This long-term extension study is an open-label, multiple-dose study to evaluate the long-term safety, tolerability, efficacy and PD of vamorolone administered once daily by liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who participated in the VBP15-002 Phase IIa and VBP15-003 Phase IIa extension core studies.

Read the detailed description

This study will evaluate if it is safe to use a new medication called vamorolone for more than two weeks in children with DMD, if boys with DMD who take the study medication have improved muscle function compared to boys with DMD in other studies who did not take any type of steroid, and to see if boys with DMD who take the study medication gain less weight compared to boys with DMD in a prior study who took another type of steroid called prednisone. Enrolled participants will take the study medication for 24 months.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • vamorolone
04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's parent or legal guardian has provided written and HIPAA authorization (if applicable) prior to any VBP15-LTE long-term extension study-specific procedures;
  2. Subject has previously completed study VBP15-003 up to and including the Week 24 Final assessments, prior to enrolling in the VBP15-LTE study at the conclusion of the VBP15-003 Week 24 Visit [Note: if entering the dose-tapering period, subject is enrolling within 8 weeks after the VBP15-003 final visit following dose-tapering]; and
  3. Subject and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subject had a serious or severe adverse event in study VBP15-003 that, in the opinion of the Investigator, was probably or definitely related to vamorolone use and precludes safe use of vamorolone for the subject in this long-term extension study;
  2. Subject has current or history of major renal or hepatic impairment, diabetes mellitus or ;
  3. Subject has current or history of chronic systemic fungal or viral infections;
  4. Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study medication;
  5. Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary];
  6. Subject is currently being treated or has received previous treatment with oral or other immunosuppressive agents [Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical glucocorticoids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration];
  7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;
  8. Subject has an allergy or to the study medication or to any of its constituents;
  9. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;
  10. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator
  11. Subject is currently taking any drug, or has taken any investigational drug other than vamorolone within 3 months prior to the start of study treatment.

Note: Subjects may be re-evaluated if ineligible due to a transient condition which would prevent the subject from participating.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Dose Level Group 1

    Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.

    Drug: Vamorolone 0.25 mg/day/day

  • Experimental
    Dose Level Group 2

    Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.

    Drug: Vamorolone 0.75 mg/day/day

  • Experimental
    Dose Level Group 3

    Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.

    Drug: Vamorolone 2.0 mg/day/day

  • Experimental
    Dose Level Group 4

    Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.

    Drug: Vamorolone 6.0 mg/day/day

Interventions

  • DrugVamorolone 0.25 mg/day/day

    Drug page: Vamorolone

    Oral administration of 0.25 mg/kg/day daily for 24 months.

    Also known as: VBP15

  • DrugVamorolone 0.75 mg/day/day

    Drug page: Vamorolone

    Oral administration of 0.75 mg/kg/day daily for 24 months.

    Also known as: VBP15

  • DrugVamorolone 2.0 mg/day/day

    Drug page: Vamorolone

    Oral administration of 2.0 mg/kg/day daily for 24 months.

    Also known as: VBP15

  • DrugVamorolone 6.0 mg/day/day

    Drug page: Vamorolone

    Oral administration of 6.0 mg/kg/day daily for 24 months.

    Also known as: VBP15

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03

    To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- month Treatment Period, in boys ages 4-7 years with DMD; Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination);

    Time frame: 24 months

  2. Total Number of Adverse Events as Assessed by CTCAE Version 4.03

    To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24-month Treatment Period, in boys ages 4-7 years with DMD. Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination).

    Time frame: 24 Months

07

Results

Posted May 20, 2021

Participant flow

Participant flow — Overall Study
MilestoneDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Started11121211
Completed1011119
Not completed1112

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03

To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- month Treatment Period, in boys ages 4-7 years with DMD; Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination);

Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03
ParticipantsDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Dose Level Group 5
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.0341429139
PrimaryTotal Number of Adverse Events as Assessed by CTCAE Version 4.03

To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24-month Treatment Period, in boys ages 4-7 years with DMD. Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination).

Time frame:
24 Months
Reported as:
Number · Events
Total Number of Adverse Events as Assessed by CTCAE Version 4.03
EventsDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Dose Level Group 5
Total Number of AEs15342035302
Total Number of TEAEs14342025300

Adverse events

Collected over Adverse events, including Serious Adverse Events (SAEs), and concomitant medications will be assessed at each study visit and recorded throughout the 24 months treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level Group 10/11 (0%)0/11 (0%)4/11 (36.4%)
Dose Level Group 20/23 (0%)1/23 (4.3%)14/23 (60.9%)
Dose Level Group 30/38 (0%)0/38 (0%)29/38 (76.3%)
Dose Level Group 40/3 (0%)0/3 (0%)1/3 (33.3%)
Dose Level Group 50/41 (0%)1/41 (2.4%)39/41 (95.1%)
Most frequent serious events
Most frequent serious events
EventDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Dose Level Group 5
PneumoniaInfections and infestations0/111/230/380/30/41
MyoglobinuriaRenal and urinary disorders0/110/230/380/31/41
Most frequent other events
Showing 10 of 41
Most frequent other events
EventDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Dose Level Group 5
DiarrhoeaGastrointestinal disorders0/111/231/381/33/41
VomitingGastrointestinal disorders1/110/235/381/37/41
UrticariaSkin and subcutaneous tissue disorders0/110/230/381/31/41
Lipids AbnormalInvestigations0/110/230/381/30/41
Gastroenteritis viralInfections and infestations0/110/230/381/32/41
NasopharyngitisInfections and infestations0/111/237/380/312/41
Weight increasedInvestigations0/110/232/380/310/41
PyrexiaGeneral disorders0/110/239/380/38/41
ConstipationGastrointestinal disorders0/110/233/380/38/41
CoughRespiratory, thoracic and mediastinal disorders1/111/237/380/38/41

Baseline characteristics

Subjects entered this study in one of 4 dose level groups, but were allowed to escalate/de-escalate during the course of the study.

Age, Continuous
Age, Continuous(years)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Mean5.87 ± 1.1355.11 ± 0.8055.13 ± .9645.27 ± 0.8565.33 ± 0.965
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Female00000
Male1112121146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Hispanic or Latino01034
Not Hispanic or Latino111112842
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American10001
White1010121143
More than one race00000
Unknown or Not Reported01001
Region of Enrollment
Region of Enrollment(participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Canada30227
Sweden04004
United States832518
United Kingdom00426
Israel03205
Australia02226
08

Study locations

12 sites
  • University of California Davis
    Davis, California 95616, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Ann & Robert H. Lurie Children's Hospital
    Chicago, Illinois 60611, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75207, United States
  • Royal Children's Hospital
    Melbourne, Australia
  • Sydney Children's Hospital
    Westmead, Australia
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Schneider Children's Medical Center
    Petah Tikwah, 49202, Israel
  • Queen Silvia Children's Hospital
    Gothenburg, 41685, Sweden
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM; CINRG VBP15 and DNHS Investigators. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020 Sep 21;17(9):e1003222. doi: 10.1371/journal.pmed.1003222. eCollection 2020 Sep. PubMed 32956407 ↗
  • Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ; NorthStar UK Network and CINRG DNHS Investigators. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2144178. doi: 10.1001/jamanetworkopen.2021.44178. PubMed 35076703 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Apr 2020, 38 months.

Results were first posted in May 2021, 1 year after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 38 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2017
First posted
Jan 31, 2017
StartActual
Feb 2, 2017
Primary completionActual
Apr 30, 2020
CompletionActual
Apr 30, 2020
Results first posted
May 20, 2021
Last update
May 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03038399
Lead sponsor
ReveraGen BioPharma, Inc.
Collaborators
University of Pittsburgh, Cooperative International Neuromuscular Research Group
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Feb 2, 2017
Primary completion
Apr 30, 2020
Completion
Apr 30, 2020
Results posted
May 20, 2021
Last update
May 20, 2021

Study contacts

Paula R Clemens, MD
study chair · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamorolone

Start the discussion